The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharide-induced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 藥學院 > 藥物化學研究所 > 期刊論文 > Item 310903500/30995

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30995

题名:	The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharide-induced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages
作者:	Ho, FM;Lai, CC;Huang, LJ;Kuo, TC;Chao, CM;Lin, WW
贡献者:	藥學院藥化所;Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 100, Taiwan;Dept Hlth, Tao Yuan Gen Hosp, Dept Internal Med, Executive Yuan, Taiwan;China Med Coll, Grad Inst Pharmaceut Chem, Taichung, Taiwan;Chia Nan Univ Pharm, Dept Cosmet Sci, Tainan, Taiwan;Natl Taiwan Univ, Coll Med, Dept Orthoped, Taipei 10018, Taiwan
日期:	2004
上传时间:	2010-09-24 15:09:07 (UTC+8)
出版者:	NATURE PUBLISHING GROUP
摘要:	Rationale. Risperidone doses for acute schizophrenia were rather high in most recent studies. Objectives. We tested a hypothesis that fine-tuning risperidone dosage to relieve side effects still yields efficacy. Clinical factors influencing the dosing were also determined. Methods. One hundred and forty-six schizophrenia inpatients with acute exacerbation entered a prospective, 6-week, repeated measures study. Risperidone doses were titrated to 6 mg/day (if tolerable) within 7 days, but were lowered thereafter if adverse reactions appeared. Efficacy and safety were measured biweekly. Results. Forty-eight patients tolerated the 6-mg/day target dose well, while the other 98 received lower final doses (mean+/-SD=3.4+/-0.9 mg/day) to curtail adverse effects. At endpoint, 64.3% of the low-dose patients and 43.8% of the high-dose subjects responded to treatment [greater than or equal to20% reduction in the Positive and Negative Syndrome Scale (PANSS) total score] (P=0.018). In detail, the low-dose individuals were significantly superior in percentage changes in the PANSS total and general-subscale scores at endpoint. The low-dose group also tended to improve more (albeit statistically insignificantly) in the PANSS positive and negative subscales and other efficacy measures. Compared to the patients with undifferentiated subtype, those with disorganized subtype received higher dosage by 0.90 mg/day, after controlling for other variables (P=0.008). Paranoid subtype was similar to undifferentiated subtype in drug doses. Patients with longer illness duration also showed a trend to use higher dosage (P=0.078). Conclusions. These findings suggest that dosage adjustment to diminish side effects does not compromise risperidone response and that disorganized patients and perhaps patients with longer illness duration are prone to receive larger doses.
關聯:	BRITISH JOURNAL OF PHARMACOLOGY 141(6):1037-1047
显示于类别:	[藥物化學研究所] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在CMUR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....